Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Immunovia ABIMMVF -61.59%27 Earnings Yield (Joel Greenblatt) % is -82.64% as of Jun. 2026. GuruFocus rates IMMVF with a GF Score™ of 27/100 and a GF Value™ of $0.01. The stock has 6 warning signs investors should review. Among 213 Medical Diagnostics & Research companies, Immunovia AB ranks worse than 95.31% on this metric.
Immunovia AB's Enterprise Value for the quarter that ended in Jun. 2026 was $10.13 Mil.
Immunovia AB's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was $-8.76 Mil. Immunovia AB's Earnings Yield (Joel Greenblatt) for the quarter that ended in Jun. 2026 was -82.64%.
The historical rank and industry rank for Immunovia AB's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
IMMVF'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -268183.71 Med: -4.35 Max: 47284.55
Current: -106.38
During the past 13 years, the highest Earnings Yield (Joel Greenblatt) of Immunovia AB was 47284.55%. The lowest was -268183.71%. And the median was -4.35%.
IMMVF's Earnings Yield (Joel Greenblatt) % is ranked worse than 95.31% of 213
companies
in the Medical Diagnostics & Research industry
Industry Median: -0.2
vs IMMVF: -106.38
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Immunovia AB's Forward Rate of Return (Yacktman) % for the quarter that ended in Jun. 2026 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Immunovia AB (OTCPK:IMMVF) Earnings Yield (Joel Greenblatt) % Explanation
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
Immunovia AB Earnings Yield (Joel Greenblatt) % Related Terms
Immunovia AB Earnings Yield (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Immunovia AB's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Immunovia AB Earnings Yield (Joel Greenblatt) % Chart
For the Diagnostics & Research subindustry, Immunovia AB's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Immunovia AB Earnings Yield (Joel Greenblatt) % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Immunovia AB's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Immunovia AB's Earnings Yield (Joel Greenblatt) % falls into.
Immunovia AB Earnings Yield (Joel Greenblatt) % Calculation
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
Immunovia ABs Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2025 is calculated as
Immunovia AB's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-8.76 Mil.
What does a Earnings Yield (Joel Greenblatt) % of -82.64% mean?
Immunovia AB (IMMVF) has a Earnings Yield (Joel Greenblatt) % of -82.64% as of Jun. 2026. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Immunovia AB and its competitors. According to the industry distribution chart, Immunovia AB ranks #203 out of 213 companies in the Medical Diagnostics & Research industry, placing it in the top 95.3%.
Is Immunovia AB's Earnings Yield (Joel Greenblatt) % too high?
Immunovia AB's current Earnings Yield (Joel Greenblatt) % is -82.64%. Based on the distribution chart, Immunovia AB ranks #203 out of 213 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Immunovia AB has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Immunovia AB's Earnings Yield (Joel Greenblatt) % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Immunovia AB ranks #203 out of 213 companies for Earnings Yield (Joel Greenblatt) %. This places Immunovia AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Medical Diagnostics & Research company?
A good Earnings Yield (Joel Greenblatt) % depends on the Medical Diagnostics & Research industry context. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Immunovia AB and its competitors. Immunovia AB's current Earnings Yield (Joel Greenblatt) % is -82.64%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Immunovia AB stock overvalued right now?
Immunovia AB (IMMVF) has a current Earnings Yield (Joel Greenblatt) % of -82.64%. The stock's GF Value™ is $0.01, compared to a current price of $0.02 — trading 100% above its estimated fair value. The current Earnings Yield (Joel Greenblatt) % is -82.64%. Immunovia AB's overall GF Score™ is 27/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For Immunovia AB (IMMVF), the current Earnings Yield (Joel Greenblatt) % is -82.64% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Immunovia AB (IMMVF) Overvalued in 2026?
Based on GuruFocus' analysis, Immunovia AB stock appears to be overvalued.
The current stock price of $0.02 is trading 100% above its estimated GF Value™ of $0.01.
Key valuation signals for IMMVF:
Earnings Yield (Joel Greenblatt) %: -82.64%
GF Value™: $0.01 vs. price of $0.02 (100% above fair value)
No single metric tells the full story. See the IMMVF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Immunovia AB is a diagnostic company. The company develops and commercializes diagnostic tools to detect proteins and autoimmune diseases. The company is developing its next-generation blood test to detect pancreatic cancer in high-risk individuals. IMMray platform is dedicated to the early detection of pancreatic cancer. Its technology platform IMMray (TM), is based on antibody microarray analysis.
27GF Score
Get the complete analysis for IMMVF
Earnings Yield (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IMMVF has been successfully added to your 
